Greater Boston’s life sciences companies continue to push beyond Kendall Square.

Third Rock Ventures and Tango Therapeutics have both signed leases at Samuels & Associates’ 201 Brookline Ave., an office and lab component in the developer’s 401 Park development in the Fenway neighborhood.

Cancer therapy biotech company Tango Therapeutics, currently based in Kendall Square, has leased 65K SF for research, clinical and translational medicine activities.

Healthcare venture firm Third Rock Ventures, which is an investor in Tango, plans to move its headquarters from Back Bay to a 24K SF office in the development, which is currently under construction. The Brookline Avenue project is near the Longwood Medical Area and a 10-minute drive from Kendall Square, the region’s leading cluster for life sciences companies.

“We’re thrilled to be anchored within The Fenway’s budding innovation scene, and excited for the opportunity to tap into the array of amenities to match the energy and diversity we hold as important to our efforts,” Third Rock Chief Operating Officer and partner Kevin Gillis said.

The deals boost Fenway’s profile as a life sciences destination. Decibel Therapeutics became the Fenway’s first lab tenant in 2017 when it moved into Samuels’ Van Ness building, and the planned second phase of the Fenway Center air rights project over the Massachusetts Turnpike is expected to include labs.

Samuels & Associates still has an additional 400K SF of available space at 201 Brookline Ave., which is slated to deliver in the spring of 2022.